These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36175917)

  • 1. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
    Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
    Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
    Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
    Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
    Mischoulon D; Hylek L; Yeung AS; Clain AJ; Baer L; Cusin C; Ionescu DF; Alpert JE; Soskin DP; Fava M
    J Affect Disord; 2017 Jan; 208():6-14. PubMed ID: 27736689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.
    Bruun KD; Amris K; Vaegter HB; Blichfeldt-Eckhardt MR; Holsgaard-Larsen A; Christensen R; Toft P
    Trials; 2021 Nov; 22(1):804. PubMed ID: 34781989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin.
    Berk M; Mohebbi M; Dean OM; Cotton SM; Chanen AM; Dodd S; Ratheesh A; Amminger GP; Phelan M; Weller A; Mackinnon A; Giorlando F; Baird S; Incerti L; Brodie RE; Ferguson NO; Rice S; Schäfer MR; Mullen E; Hetrick S; Kerr M; Harrigan SM; Quinn AL; Mazza C; McGorry P; Davey CG
    BMC Med; 2020 Jan; 18(1):16. PubMed ID: 31948461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
    Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
    Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo.
    Sampson E; Mills NT; Hori H; Cearns M; Schwarte K; Hohoff C; Oliver Schubert K; Fourrier C; Baune BT
    Brain Behav Immun; 2025 Jan; 123():43-56. PubMed ID: 39243988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.
    Quinn AL; Dean OM; Davey CG; Kerr M; Harrigan SM; Cotton SM; Chanen AM; Dodd S; Ratheesh A; Amminger GP; Phelan M; Williams A; Mackinnon A; Giorlando F; Baird S; Rice S; O'Shea M; Schäfer MR; Mullen E; Hetrick S; McGorry P; Berk M
    Early Interv Psychiatry; 2018 Feb; 12(1):45-54. PubMed ID: 26542332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
    Kavakbasi E; Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert KO; Clark SR; Fourrier C; Baune BT
    J Neurochem; 2024 Sep; 168(9):1817-1825. PubMed ID: 37635396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of eicosapentaenoic acid in inflammatory depression: study protocol for a match-mismatch trial.
    Suneson K; Ängeby F; Lindahl J; Söderberg G; Tjernberg J; Lindqvist D
    BMC Psychiatry; 2022 Dec; 22(1):801. PubMed ID: 36536364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.
    Daldegan-Bueno D; Donegan CJ; Forsyth A; Sumner RL; Murphy RJ; Menkes DB; Evans W; Hoeh N; Sundram F; Reynolds LM; Ponton R; Cavadino A; Smith T; Roop P; Allen N; Abeysinghe B; Svirskis D; Bansal M; Muthukumaraswamy S
    Trials; 2024 Aug; 25(1):560. PubMed ID: 39182140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
    Yang C; Bosker FJ; Li J; Schoevers RA
    BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial.
    Wessa C; Janssens J; Coppens V; El Abdellati K; Vergaelen E; van den Ameele S; Baeken C; Zeeuws D; Milaneschi Y; Lamers F; Penninx B; Claes S; Morrens M; De Picker L
    Brain Behav Immun Health; 2024 Nov; 41():100871. PubMed ID: 39350954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
    Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
    BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutritional counselling in adults promoting adherence to the Mediterranean diet as adjuvant in the treatment of major depressive disorder (INDEPT): a randomized open controlled trial study protocol.
    Sousa-Santos N; Fialho M; Madeira T; Clara C; Veiga S; Martins R; Barros N; Santos G; Santos O; Almeida C; Ganança L; Campos RC; Camolas J; da Silva AP; Guarino MPS; Heitor MJ
    BMC Psychiatry; 2023 Apr; 23(1):227. PubMed ID: 37016319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for Anti-inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial.
    Abbasian F; Bagheri S; Moradi K; Keykhaei M; Etemadi A; Shalbafan M; Shariati B; Vaseghi S; Samsami FS; Akhondzadeh S
    Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):128-134. PubMed ID: 36093920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.